Lonvita has completed a mandatory public tender offer for the shares of Health Italia
March 2026 — Lonvita S.p.A. has completed a mandatory public tender offer for the shares of Health Italia S.p.A.
Lonvita is an investment vehicle established to facilitate a club transaction that acquired a controlling stake in Health Italia. It serves as the holding company through which promoters Giovanni Giuliani and Stefano Pellegrino, together with participating investors, structured the acquisition in the supplementary healthcare sector, including management reinvestment.
Founded in 2001, Health Italia is leading provider of supplementary healthcare services, offering mutualistic solutions, welfare services and telemedicine through a network of more than 8,000 affiliated facilities. The entrepreneurial project, led by Giuliani and Pellegrino, aims to further enhance the company’s assets, strengthen its distribution platform and expand its offering through targeted investments in marketing and technology, while leveraging the expertise of Health Italia’s management team. As Health Italia is a listed company, its shareholder base is widely dispersed.
Our role in the transaction
Oaklins Italy’s parent company, Banca Akros, served as the financial advisor and appointed broker for the collection of shares in Lonvita’s mandatory public tender offer for 31.6% of Health Italia’s shares.
Talk to the deal team
Related deals
Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.
Learn moreVeremark has completed a secondary share sale
Veremark, the global workplace trust company, has completed an employee and early investor secondary share sale, on the London Stock Exchange’s (LSE) Private Securities Market (PSM), valuing the company at over US$133 million in enterprise value. Crowdcube, Europe’s leading private market liquidity platform, managed the transaction.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn more